Get the Stockscreener App
10.98
4.17%
0.44
Syndax Pharmaceuticals Inc stock is traded at $10.98, with a volume of 3.03M.
It is up +4.17% in the last 24 hours and down -20.03% over the past month.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
See More
Previous Close:
$10.54
Open:
$10.51
24h Volume:
3.03M
Relative Volume:
1.38
Market Cap:
$944.83M
Revenue:
$139.71M
Net Income/Loss:
$-209.36M
P/E Ratio:
-3.7095
EPS:
-2.96
Net Cash Flow:
$-160.60M
1W Performance:
+11.47%
1M Performance:
-20.03%
6M Performance:
-34.25%
1Y Performance:
-43.02%
1-Day Range:
$10.47
$11.36
1-Week Range:
$9.73
$11.36
52-Week Range:
$8.58
$25.07
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Name
Syndax Pharmaceuticals Inc
Sector
Industry
Phone
781-419-1400
Address
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
10.98 | 854.45M | 139.71M | -209.36M | -160.60M | -2.96 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-24 | Initiated | UBS | Buy |
| Jun-28-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Oct-25-23 | Initiated | BofA Securities | Buy |
| Oct-11-23 | Initiated | Goldman | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-11-23 | Initiated | Guggenheim | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jan-03-23 | Initiated | JP Morgan | Overweight |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Apr-11-22 | Initiated | H.C. Wainwright | Buy |
| Feb-15-22 | Initiated | Goldman | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-25-21 | Initiated | Citigroup | Buy |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| May-22-20 | Upgrade | Citigroup | Neutral → Buy |
| May-22-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-18-20 | Downgrade | Citigroup | Buy → Neutral |
| May-11-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-08-19 | Reiterated | H.C. Wainwright | Buy |
| Jan-04-19 | Initiated | Robert W. Baird | Outperform |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Mar-16-17 | Initiated | FBR & Co. | Outperform |
| Mar-02-17 | Initiated | Instinet | Buy |
| Oct-07-16 | Initiated | Guggenheim | Buy |
| Mar-28-16 | Initiated | Citigroup | Buy |
| Mar-28-16 | Initiated | JMP Securities | Mkt Outperform |
| Mar-28-16 | Initiated | Morgan Stanley | Overweight |
View All
Syndax Pharmaceuticals Inc Stock (SNDX) Latest News
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading 4.9% HigherShould You Buy? - MarketBeat
Nuveen Asset Management LLC Lowers Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
84,998 Shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Purchased by Polar Asset Management Partners Inc. - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Wellington Management Group LLP - MarketBeat
Bank of America Corp DE Sells 546,799 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Millennium Management LLC Decreases Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Voloridge Investment Management LLC Takes $1.05 Million Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Two Sigma Investments LP - MarketBeat
Syndax Announces Participation in June Investor Conferences | SN - GuruFocus
Syndax Announces Participation in June Investor Conferences - GlobeNewswire
Two Sigma Advisers LP Has $7.09 Million Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 5.7%Here's Why - MarketBeat
Syndax Pharmaceuticals at 6th Annual Oncology Innovation: Strategic Insights - Investing.com Australia
Syndax Pharmaceuticals at 6th Annual Oncology Innovation: Strategic Insights By Investing.com - Investing.com Canada
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Millennium Management LLC Has $7.76 Million Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Man Group plc Acquires New Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Bought by Deutsche Bank AG - Defense World
Twinbeech Capital LP Increases Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
(SNDX) Trading Advice - news.stocktradersdaily.com
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 5.7% – Here’s What Happened - Defense World
Soleus Capital Management L.P. Buys 1,401,016 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
#ASCO25: Kura spells out pivotal AML trial win as it gears up to compete with Syndax - Endpoints News
D. E. Shaw & Co. Inc. Sells 168,241 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Tang Capital Management LLC Acquires Shares of 100,000 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Polar Asset Management Partners Inc. Takes $1.12 Million Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Investor Network: Syndax Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Nicholas Botwood Bought 50% More Shares In Syndax Pharmaceuticals - simplywall.st
D. E. Shaw & Co. Inc. Lowers Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Balyasny Asset Management L.P. Sells 297,591 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Prosight Management LP Grows Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Bought by BNP Paribas Financial Markets - MarketBeat
Insider Buying: Keith Katkin Acquires Additional Shares of Synda - GuruFocus
Northern Trust Corp Grows Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Ensign Peak Advisors Inc Sells 93,876 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax (SNDX) Sees Insider Buying Activity Boost | SNDX Stock Ne - GuruFocus
Recent Insider Transactions at Syndax Pharmaceuticals - TradingView
Hudson Bay Capital Management LP Lowers Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Dimensional Fund Advisors LP Purchases 283,577 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Sphera Funds Management LTD. Raises Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Octagon Capital Advisors LP Invests $11.95 Million in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by The Manufacturers Life Insurance Company - Defense World
Syndax Pharmaceuticals Inc Stock (SNDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):